JCM
ANAB icon

Jafra Capital Management’s AnaptysBio ANAB Stock Holding History

Jafra Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,095
Closed -$211K – 85
2017
Q4 		$211K Sell
2,095
-12,926
-86% -$952K 0.06% 83
2017
Q3 		$525K Buy
+15,021
New +$405K 0.2% 64

Other funds holding ANAB

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jafra Capital Management's ANAB Position: Q1 2018 in Review

Jafra Capital Management sold out of AnaptysBio (ANAB) in Q1 2018, closing a stake of 2,095 shares — an estimated $211K sold.

Jafra Capital Management first reported a position in ANAB in Q3 2017 and held it in 2 quarters. The position peaked at $525K in Q3 2017. 134 funds tracked by Wall St. Rank hold ANAB as of Q1 2018.

  • Jafra Capital Management reported no remaining AnaptysBio position as of Q1 2018 after selling out during the quarter.
  • Jafra Capital Management sold 2,095 AnaptysBio shares in Q1 2018, an estimated $211K.
  • Jafra Capital Management first reported a position in AnaptysBio in Q3 2017 and held it in 2 quarters.
  • Jafra Capital Management's AnaptysBio position peaked at $525K in Q3 2017.
  • 134 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2018.

Based on Jafra Capital Management's 13F filing for Q1 2018, filed 23 Apr 2018.